Tuoli Xiaodu powder ameliorated 5-fluorouracil-induced intestinal injury by reducing intestinal inflammation, oxidative stress, and intestinal flora imbalance

Simple item page
dc.contributor.authorLing Jiang
dc.contributor.authorWanrou Jiang
dc.contributor.authorWanyi Zhang
dc.contributor.authorWenjuan Zheng
dc.contributor.authorHongjie Huang
dc.contributor.authorYu Xia
dc.contributor.authorXiuyun He
dc.contributor.authorChaofu Zhu
dc.contributor.authorYongjun Wu
dc.contributor.departmentBiología Celular e Histología
dc.date.accessioned2025-12-22T08:55:52Z
dc.date.available2025-12-22T08:55:52Z
dc.date.issued2026
dc.description.abstractChemotherapy-induced diarrhea (CID) is a common adverse event in cancer patients treated with 5-fluorouracil (5-FU). This study aimed to investigate the potential protective effects of Tuoli Xiaodu (TLXD) powder on CID and to explore its possible mechanisms. Mice with CID induced by 5-FU were randomly divided into seven groups: Blank group, CID group, positive drug (loperamide) group, and TLXD powder low, medium, and high groups. The degree of diarrhea, tumor growth, intestinal barrier damage, intestinal inflammation, oxidative stress, and gut microbiota diversity were assessed. The study showed that TLXD powder significantly inhibited diarrhea and tumor growth in 5-FU-induced CID mice. H&E staining and western blot showed that TLXD powder improved the intestinal mucosa and intestinal permeability of 5-FU-induced CID mice. Furthermore, TLXD powder elicited a reduction in the expression of inflammatory factors within the intestinal tract of mice with CID while simultaneously augmenting the expression of anti-inflammatory factors and maintaining a balanced Th17/Treg ratio. TLXD powder decreased intestinal oxidative stress and intestinal epithelial cell ferroptosis and activated the Nrf2/HO-1 signaling axis in CID mice. The results of the gut flora analysis showed that TLXD powder improved the intestinal flora structure of CID mice. TLXD powder significantly reduced the proportion of Proteobacteria, Actinobacteria, Deferribacteres, and TM7 at the phylum level and Desulfovibrio, Mucispirillum, Adlercreutzia, and Odoribacter at the genus level. These findings provide a new therapeutic approach for the management of CID in cancer patients treated with 5-FU
dc.formatapplication/pdf
dc.format.extent15
dc.identifier.doihttps://doi.org/10.14670/HH-18-935
dc.identifier.eissn1699-5848
dc.identifier.issn0213-3911
dc.identifier.urihttp://hdl.handle.net/10201/181830
dc.languageeng
dc.publisherUniversidad de Murcia, Departamento de Biologia Celular e Histiologia
dc.relationSin financiacion externa a la Universidad
dc.rightsAttribution-NonCommercial-NoDerivatives 4.0 International*
dc.rights.accessRightsinfo:eu-repo/semantics/openAccess
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/4.0/*
dc.subjectChemotherapy-induced diarrhea
dc.subjectTuoli Xiaodu powder
dc.subjectInflammation
dc.subjectOxidative stress
dc.subjectIntestinal mucosal injury
dc.subjectIntestinal microflora
dc.subjectColorectal cancer
dc.subject.odsNo relacionado con ningún objetivo de desarrollo sostenible
dc.titleTuoli Xiaodu powder ameliorated 5-fluorouracil-induced intestinal injury by reducing intestinal inflammation, oxidative stress, and intestinal flora imbalance
dc.typeinfo:eu-repo/semantics/article
Files
Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
Wu-41-135-149-2026.pdf
Size:
16.68 MB
Format:
Adobe Portable Document Format
Description:
Download
License bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
license.txt
Size:
1.37 KB
Format:
Item-specific license agreed upon to submission
Description:
Download
Collections
Histology and histopathology, Vol.41, Nº1, (2026)